MarketInOut Stock Screener Log In | Sign Up
 

Corcept Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 08/21/2026 16:00
Corcept Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization12,983 mln
Float96.36 mln
Earnings Date11/04/2026

EPS

0.45
Overpriced

P / E

272
Bubble territory

Piotroski F-Score

4 / 9
Borderline

Beneish M-Score

-3.3
Reliable

1-Year Forecast

141
Attractive

Relative Strength

88 / 100
Strongly outperforming

Business Description

Corcept Therapeutics is a US-based pharmaceutical company focused on developing drugs that target the effects of cortisol, a hormone that can cause serious harm when the body produces too much of it. Its main product, Korlym, is an approved oral treatment for adults with Cushing's syndrome whose excess cortisol has led to blood sugar problems and who cannot or did not benefit from surgery. The company also has several additional compounds in various stages of clinical testing, targeting conditions such as liver disease and ALS. Founded in 1998 and based in Redwood City, California, Corcept has built its entire business around understanding and controlling cortisol's role in disease.

Key Fundamentals

EPS0.45
P/E272
ROE8.47
RPS7.16
ROIC1.41
ROA6.62
EBITDA, mln8.82
EV / EBITDA1,402
EV / EBIT1,932
Revenue, mln831
EV / Revenue14.89

Financial Strength

Altman Z-Score36.3
Piotroski F-Score 4 / 9
Beneish M-Score-3.3
Price to Graham Number16.00
1-Year Target Price141
Shiller PE Ratio129
Short Ratio7.42
Short % of Float11.70

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 6.8% 89 / 100   
1 Month 26.47% 93 / 100   
2 Months 110% 99 / 100   
6 Months 251% 99 / 100   
1 Year 73.65% 91 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us